Vascular endothelial growth factor-121 mRNA expression and neomicrovessel density in primary lung cancer

Ohta, Yasuhiko; Watanabe, Yoh; Oda, Makoto; Hayashi, Yoshinobu; Endo, Yuichi; Sasaki, Takuma

doi:10.3892/or.3.4.713

Cited by 60 publications

(97 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The result is consistent with that of the previous similar analysis with primary lung cancer tissue. 4 In all cells tested, H157, A427, N417, H358 and SKOV3.ipl showed relatively high expression of VEGF mRNA, while the BEAS-2B cells showed a less intense band than the cancer cell lines, although the band corresponding to VEGF121 was detected at very low levels. Furthermore, we investigated the correlation between mRNA expression and protein expression for VEGF.…”

Section: Vegf Mrna and Protein Expression In Various Cell Linesmentioning

confidence: 82%

“…25 Analysis of VEGF RNA expression The VEGF RNA status of cell lines was analyzed by RT-PCR as described previously. 4 Total cellular RNA was extracted from 1 Â 10 7 cells using the RNeasy kit (Qiagen, Valencia, CA) and analyzed for VEGF and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) RNA with the GeneAmp RNA PCR core kit (Applied Biosystems), as described by the manufacturer. Briefly, 500 ng of total RNA was reverse-transcribed with the random hexamer and murine leukemia virus reverse transcriptase (501C 30 min) and amplified by PCR with 50 nM of primer pairs described below using a cycling program (initial step of 951C for 15 min, 27 cycles of 951C for 1 min and 601C for 1 min and 721C for 1 min, final step of 721C for 10 min).…”

Section: Adenovirus Vectorsmentioning

confidence: 99%

“…In vitro, we first investigated a panel of 12 NSCLC cell lines, one bronchial epithelial cell line (BEAS-2B) as a normal cell control, one ovarian cancer cell line (SKOV3.ipl), one gastric cancer cell line (MKN28), and a pancreatic cancer cell line (Panc-I) for VEGF expression using a RT-PCR method as reported previously. 4 There are four structural variants of VEGF (VEGF121, VEGF165, VEGF189 and VEGF206) resulting from alternative mRNA splicing in the regions encoding the cytoplasmic domains. Figure 2a shows amplification of a 408 bp fragment (representing VEGF121 cDNA) and a 541 bp fragment (representing VEGF165 cDNA) in all cell lines tested.…”

Section: Vegf Mrna and Protein Expression In Various Cell Linesmentioning

confidence: 99%

“…In fact, several papers have reported that the resected lung cancer tissue express the VEGF mRNA and protein abundantly based on immunohistochemical and reverse transcription-polymerase chain reaction (RT-PCR) analysis. 4,5 Moreover, the high expression levels of VEGF mRNA and protein are correlated with poor prognosis in lung cancer patients, 4,5 indicating that advanced lung cancer tissues tend to express VEGF. We also reported the negative correlation between VEGF expression and dendritic cell infiltration in the tumor, suggesting an immunosuppressive function of VEGF, which may promote the tumor growth.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

Takayama

Adachi

et al. 2006

Cancer Gene Ther

View full text Add to dashboard Cite

Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.

show abstract

Section: Vegf Mrna and Protein Expression In Various Cell Linesmentioning

confidence: 82%

Section: Adenovirus Vectorsmentioning

confidence: 99%

Section: Vegf Mrna and Protein Expression In Various Cell Linesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

Takayama

Adachi

et al. 2006

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…Further prospective studies have to clarify whether CSF VEGF levels may serve for risk stratification of patients in studies with LM. The value of VEGF as a prognostic factor also corresponds to the fact that increased VEGF is also an independent negative prognostic factor in systemic tumours and solid brain tumours (Berkman et al, 1993;Ohta et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value

et al. 2004

View full text Add to dashboard Cite

This study examined the diagnostic and prognostic value of vascular endothelial growth factor (VEGF) levels in the cerebrospinal fluid (CSF) of 39 patients with leptomeningeal metastasis (LM). Vascular endothelial growth factor levels at diagnosis were significantly higher in patients with LM (median 359 pg ml À1 ) than in patients with other neurological diseases (median o25 pg ml À1 ). The specificity of VEGF levels above 250 pg ml À1 for LM was high (98.3%), while the sensitivity was low (51.4%; 73% for VEGF values above 100 pg ml À1 ). In 49% of the LM patients, particularly with lymphoma or medulloblastoma, VEGF levels were below 250 pg ml À1 and thus in the range of VEGF levels in other neurological diseases. Vascular endothelial growth factor levels correlated significantly with CSF lactate and albumin. Vascular endothelial growth factor levels mirrored the clinical course with a marked reduction in response to therapy and an increase at relapse in some patients who had serial CSF samples available. Multivariate Cox regression analysis showed VEGF below 100 pg ml À1 (relative risk (RR) ¼ 4.24, P ¼ 0.0002) and age below 60 years (RR ¼ 2.5, P ¼ 0.004) to be associated with longer survival in LM. In conclusion, CSF VEGF levels in LM vary considerably. High VEGF levels have a very high specifity for LM and may help to establish the diagnosis. The role of VEGF as a predictor of outcome should be substantiated in prospective studies.

show abstract

Short Interfering RNA–Mediated Gene Silencing of Vascular Endothelial Growth Factor

et al. 2006

View full text Add to dashboard Cite

Hypothesis: By using short interfering RNA (siRNA) to inhibit the in vitro expression of vascular endothelial growth factor (VEGF) A, we hope to further investigate the presence of an autocrine loop in colon cancer cells. We hypothesize that VEGF inhibition will result in decreased cellular proliferation. Design: Human colon cancer cells were evaluated for the expression of VEGF and VEGF receptor 2 (VEGFR-2). In vitro assessments were then made of the ability of anti-VEGF siRNA to knock down expression of VEGF and the subsequent effect this decreased expression had on colon cancer cell proliferation. Setting: Surgical oncology research laboratory. Interventions: Human colon cancer cells from the RKO cell line were transfected with siRNA targeting the coding region of VEGF. Main Outcome Measures: Enzyme-linked immunosorbent assay, Northern blot analysis, and real-time quantitative polymerase chain reaction were performed to establish the ability of siRNA to decrease VEGF production. Proliferation assays were run on transfected and wildtype cells to establish concomitant decrease in VEGF expression and cellular proliferation. Results: The RKO colon cancer cells expressed both VEGF and VEGFR-2. Those cells transfected with siRNA targeting VEGF showed a 94% knockdown in VEGF expression and a 67% decrease in cellular proliferation. Conclusion: Colon cancer cells expressing VEGF and VEGFR-2 may possess an autocrine growth pathway that can be effectively targeted using RNA interference as an antiangiogenic therapy.

show abstract

Vascular endothelial growth factor-121 mRNA expression and neomicrovessel density in primary lung cancer

Cited by 60 publications

References 0 publications

Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application

Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value

Short Interfering RNA–Mediated Gene Silencing of Vascular Endothelial Growth Factor

Contact Info

Product

Resources

About